Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Anthony Letai sworn in as 18th NCI director
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research - Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation